<DOC>
	<DOC>NCT01214421</DOC>
	<brief_summary>To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from baseline (from trial 156-04-251) in total kidney volume (TKV) and renal function.</brief_summary>
	<brief_title>Open-Label Tolvaptan Study in Subjects With ADPKD</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Subjects who have successfully completed a Phase 1, 2, or 3 tolvaptan ADPKD or renal impairment trial, with a confirmed diagnosis of ADPKD Subjects unable to provide written informed consent Subjects (men or women) who will not adhere to the reproductive precautions as outlined in the Informed Consent Form Subjects (women only) with a positive urine pregnancy test Subjects who are pregnant or breastfeeding Subjects unable to take oral medications Subjects who have allergic reactions to tolvaptan or chemically related structures such as benzazepines (benzazepril, conivaptan, fenoldopam mesylate or mirtazapine) Subjects who have disorders in thirst recognition or an inability to access fluids Subjects with critical electrolyte imbalances, as determined by the investigator Subjects with or at risk of significant hypovolemia, as determined by investigator Subjects with anemia, as determined by investigator Subjects with a history of substance abuse (within the last 3 years) Subjects taking other experimental (ie, nonmarketed) therapies or current participation in another clinical drug or device trial; current participation in the offdrug followup period of another ADPKD trial with tolvaptan is permitted Efficacy Analysis Subjects unable to complete MRI assessments(eg, subjects with ferromagnetic prostheses, aneurysm clips, severe claustrophobia) Subjects who have taken a vasopressin antagonist (outside of previous participation in a tolvaptan trial) Subjects unable to comply with antihypertensive or other important medical therapy Subjects with advanced diabetes Subjects taking medications or having an illness that could confound endpoint assessments (including taking approved therapies for the purpose of affecting PKD cysts)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Kidney Disease</keyword>
	<keyword>ADPKD</keyword>
	<keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
	<keyword>Adult Polycystic Kidney Disease</keyword>
</DOC>